Company profile
Pacira BioSciences, Inc.
NASDAQ: PCRX · Healthcare · Drug Manufacturers - Specialty & Generic
#184 of 1,422 Healthcare companies by revenue46th-percentile growth
EA Score
78B+FH 79DQ 87GM 59SS 77
v0.1 · 65/100 weight · provisional
↑ Piotroski F, disclosure history · ↓ revenue growth (YoY), 3-yr revenue growth
Methodology →Revenue TTM
$734.9M
Rev growth YoY (TTM)
+4.6%
Net income (FY)
$7.0M
Employees
827
as of 2026-08-10
Market cap
$984.2M
as of 2026-08-10
Financials — latest annual
SEC EDGAR · USD-normalizedConceptUSDNativeFY
Revenue$726.4M$726.4M2025
Net income$7.0M$7.0M2025
Operating income$19.2M$19.2M2025
Total assets$1.3B$1.3B2025
Liabilities$571.8M$571.8M2025
Equity$693.1M$693.1M2025
Revenue trend
FY2020 – FY2025 · USD
FY20
FY20
FY20
FY21
FY22
FY23
FY25
FY25
Revenue by segment
Filed disclosures · FY2025
By product
Product51%
EXPAREL40%
ZILRETTA8%
Bupivacaine Liposome Injectable Suspension0%
By geography
Not disclosed.
The read
What is Pacira BioSciences, Inc.’s revenue?
Pacira BioSciences, Inc. booked $726.4M in FY2025 revenue, growing 3.6% year over year — about the middle of the pack among Healthcare companies we track, at a 1.0% net margin.
Peers · Healthcare
Emergent BioSolutions Inc.69BRepligen Corporation82B+NeoGenomics, Inc.72BAmphastar Pharmaceuticals, Inc.77B+Supernus Pharmaceuticals, Inc.76B+Sienna Senior Living Inc.75B+Neighbors
Hillsborough →Key facts
CEOFrank D. Lee
SectorHealthcare
IndustryDrug Manufacturers - Specialty & Generic
HeadquartersTampa, FL
ExchangeNASDAQ: PCRX
Employees827
IPO date2011-02-03
Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.